Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 18 to 45 Men only

How VV913 behaves after different meals in healthy adults

Official title: Study of Food Effects of VV913 Capsules in Chinese Healthy Volunteers

Run by Vigonvita Life Sciences · NCT07565792 · Data updated 2026-11-12

This study tests how a single dose of VV913 is absorbed in healthy adult men when taken with a high-fat meal versus a standard meal.

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years to 45 Years
SexMen only
Enrollment12 (estimated)
SponsorVigonvita Life Sciences
Industry-sponsored
Locations1 site (Hefei, Anhui)
StatusRecruiting
StartedMay 11, 2026
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedJuly 14, 2026
Trial IDNCT07565792 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Healthy male adults aged 18 to 45 with BMI 19–26 kg/m2 who can use contraception during the study and for 3 months after.

Probably not a fit

Individuals with known hypersensitivity to VV913 components or those with certain medical or allergic conditions may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, randomized, open-label, 3x3 crossover Phase 1 study conducted in healthy Chinese adults to compare the pharmacokinetics of one oral dose of VV913 after high-fat and standard meals. Participants receive VV913 under different meal conditions to see how food type affects drug absorption and exposure. The trial uses a crossover design so each participant experiences all meal conditions, reducing variability. Key safety assessments include vital signs, labs, and adverse events. The study is sponsored by Vigonvita Life Sciences and located at The First Affiliated Hospital of Anhui Medical University in Hefei.

Why it matters

Potential benefit: If successful, results could help optimize how VV913 is dosed with meals to improve consistent drug exposure.

How similar studies have gone: Similar crossover pharmacokinetic studies are common in early development to understand food effects on drug absorption.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Aged 18 to 45 years old, males ;
2. Males weight no less than 50 kg, with body mass index of 19 to 26 kg/m\^2;
3. Vital signs examination, physical examination, laboratory examination ,Chest X-ray are normal or considered abnormal without clinical significance by the investigator;
4. Participants who are willing to take proper contraceptive methods during the study and within 3 months after the the last administration;
5. Participants who are able to understand and follow the study protocol and instructions; participants who have voluntarily decided to participate in this study, and sign the informed consent form.

Exclusion Criteria:

1. Participants with hypersensitivity to preparation or any of the excipients;
2. Participants with allergic constitution (such as asthma, urticaria, eczematous dermatitis and other allergic diseases), or have a history of drug or food allergy;
3. Participants with central nervous system, cardiovascular system, gastrointestinal, respiratory system, urinary, hematologic, or metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials; Participants with a history of gastrointestinal conditions that may impair drug absorption (e.g., gastrectomy or small intestine resection, atrophic gastritis, gastrointestinal ulcers or perforations/fistulas, gastrointestinal bleeding, or obstruction);
4. Participants with a history of surgery within 3 months before screening, or have not recovered from surgery, or have an expected surgical plan during the trial;
5. Participants with a blood donation or blood loss ≥ 400 mL within 3 months before screening, or a history of blood product use within 3 months before screening;
6. Participating in any clinical trial and taking clinical trial drugs within 90 days before screening;
7. Participants who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before screening;
8. Participants who have received vaccination within 14 days before screening, or planned to receive any vaccine during the trial or within 1 week after the end of the study;
9. Participants with a history of drug abuse within 1 year before screening or positive urine drug screening within 1 year before screening results (morphine, tetrahydrocannabinol, methamphetamine, dimethylene diphenazine , ketamine, and cocaine);
10. Participants who drink more than 14 standard units or at least twice a day per week within one year before screening (one standard unit equals 200 mL of beer with 5% alcohol or 25 mL of spirits with 40% alcohol content or 85 mL of wine with 12% alcohol content);
11. Participants who smoke more than 5 cigarettes a day within one year before screening;
12. Participants who can't quit smoking or drinking during the trial period;
13. Participants who are positive for hepatitis B virus surface antigen, hepatitis C virus antibody, treponema pallidum antibody or human immunodeficiency virus antibody (Anti-HIV);
14. Having special requirements for food, unable to observe a unified diet or having dysphagia;
15. Participants who cannot avoid consuming drinks containing xanthine (such as coffee and tea) or foods (such as chocolate and animal liver), or fruits or juices (such as grapefruit, pomelo, mango, and dragon fruit) that may affect drug metabolism,from 48 hours before administration until the end of the study;
16. Participants who cannot tolerate blood collection with intravenous indwelling needles or blood fainting;
17. Participants with difficulty in swallowing capsules;
18. Participants whose female partners plan to conceive within 3 months;
19. The investigator believes that there are other unsuitable factors to participate this trial.

Where it's running

  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
    Recruiting

Study contacts

  • Principal investigator: Huan Zhou — The First Affiliated Hospital of Anhui Medical University
  • Study coordinator: Huaqing Duan
  • Email: huaqing.duan@vigonvita.cn
  • Phone: 18061926005

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.